Dizhe Pharmaceutical announced that the company's chairman and CEO Zhang Xiaolin, deputy general manager and chief medical officer Yang Zhenfan, deputy general manager and chief commercial officer Wu Qingyi, and deputy general manager Zhang Zhiwei intend to reduce their holdings of the company due to personal financial needs. Among them, Zhang Xiaolin plans to reduce her holdings by no more than 2.258,500 shares, accounting for 0.4856% of the total share capital; Yang Zhenfan plans to reduce her holdings by no more than 9255,500 shares, accounting for 0.1990% of the total share capital; Wu Qingyi plans to reduce her holdings by no more than 4261,000 shares, accounting for 0.0917% of the total share capital; and Zhang Zhiwei plans to reduce her holdings by no more than 10,000 shares, accounting for 0.0022% of the total share capital. The holdings reduction period is from September 29, 2026 to December 28, 2026. The holdings reduction price is determined according to the market price during the implementation period. The amount of holdings reduction this time does not exceed 25% of the current shareholders' holdings.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.